Clinical Tolerance of an Intraparotid Injection of Bupivacaine, Combined With Dexamethasone, After Parotidectomy for Benign Tumor

There has been a paradigm shift toward less invasive surgical techniques for parotidectomies, primarily to mitigate post-surgical complications. However, preserving more parotid tissue than with traditional methods can lead to an increased incidence of salivary fistulas and sialoceles after parotidectomy. The incidence of sialoceles varies considerably from 4.9% to 39%, while salivary fistula rates after parotidectomy range from 1% to 21%. Other wound complications, such as wound dehiscence, inflammation, and infection, can also occur, typically within the first month following surgery. No pre

Trial Details

NCT ID
NCT07812259
Phase
EARLY_PHASE1
Sponsor
Centre Hospitalier Universitaire de Nīmes
Status
RECRUITING
Cancer Type
Salivary Gland Head and Neck Cancer
Interventions
  • Intraparotid injection of bupivacaine/ dexamethasone
Locations (sample)
  • Nîmes, France|43.83665,4.35788

Key Eligibility Criteria

  • Validated surgical indication for partial parotidectomy for parotid tumor.
  • The patient must have given their free and informed consent and signed the consent form
  • The patient must be a member or beneficiary of a health insurance plan

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Salivary Gland Head and Neck Cancer Trials on Trialify →